Agios Pharmaceuticals (AGIO) Liabilities and Shareholders Equity (2012 - 2026)

Agios Pharmaceuticals' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 23.82% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 billion (down 7.68% YoY) and the FY2025 annual result came in at $1.3 billion, down 22.0% from the prior year.
• Liabilities and Shareholders Equity was $1.2 billion for Q1 2026 at Agios Pharmaceuticals, down from $1.3 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.8 billion in Q3 2024 and bottomed at $773.1 million in Q2 2024.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 46.32% — and 2025, when it soared 90.31%.
• Agios Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then decreased by 24.35% to $937.1 million in 2023, then soared by 77.48% to $1.7 billion in 2024, then dropped by 22.0% to $1.3 billion in 2025, then retreated by 8.65% to $1.2 billion in 2026.
• Business Quant data shows AGIO's Liabilities and Shareholders Equity at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.